Cipla, Roche Team Up for Cancer Drug Distribution in Country
Global Pharma firm, Cipla Ltd. and Roche Products (India) Private Limited have now signed a distribution agreement for the promotion and sale of tocilizumab and the 2nd brand of bevacizumab.
The bevacizumab Injection contains human framework regions with antigen-binding regions of a humanised murine antibody that binds to VEGF. Various Clinical trials have proven its efficacy and safety in different solid tumours and is approved by regulators worldwide for certain type of brain tumour, cancers of the kidney, lung, colon and rectum and certain types of gynecological cancers viz. ovarian cancer and cervical cancers. It is usually given as part of a combination of cancer medicines.
This partnership is in line with Cipla and Roche’s efforts to improve healthcare and increase access to innovative, life-changing medicines in India, particularly to patients who currently do not have access to them.
Umang Vohra, MD & Global CEO Cipla said: “The prevalence of cancer and rheumatoid arthritis is widely spread across India, and Cipla can contribute to provide broader access to innovative medicines like tocilizumab and bevacizumab. We look forward to promote and distribute the drugs in India in furtherance to our philosophy of Caring for Life.”
Lara Bezerra, Managing Director – Roche Pharma India said: “At Roche, improving access to the critical medicines that patients need is an integral part of what we do. We believe that everyone who needs our medicines should be able to access and benefit from them. This partnership will significantly advance our efforts to expand the reach of, and improve access to, our innovative medicines. This will also enable us at Roche to focus on bringing new, transformative medicines to patients in India. As Roche, we will continue to collaborate with various stakeholders to help transform healthcare in India.”